Parkinson’s disease is a degenerative neurological disease, which is characterized by the preferential death of dopaminergic neurons in the Substantia Nigra. Current drug treatments are aimed primarily for the treatment of symptoms to improve the quality of life. Therefore, there is a need to find out new therapeutic strategies that not only provide relief but also halt or reverse the neuronal damage hampering PD progression, thus this research therefore aimed at investigating the impact of Cellgevity® on the activity of catalase in Rat Model of Parkinson disease.
Fifty four (54) male wistar rats weighing between 100-160g were purchased and randomly divided into two major groups which are the pretreated and post treated group respectively. The pre-treated and post-treated group are divided into three (3) subgroup with group A serving as the control, Group B as the Parkinson pre-treated/post-treated group and Group C as Parkinson pre-untreated/post-untreated group. Neurobehavioral test was done to confirm the induction of diabetes. At the end of the experiment, all animals were sacrifice and blood collected for Catalase Activity.
Result obtained from this study showed that there was a reduction in catalase activity when compared with the normal control untreated control rats. The treatment with cellgevity supplement in both Parkinson pre-treated and Parkinson post treatment led to an elevation in the Catalase concentration when compared with the Parkinson untreated rats.
Parkinson disease led to a reduction in the Catalase Activity. The reduced catalase activity was however elevated upon treatment with cellgevity supplement
